Breaking News

A slashed vaccine schedule & a breakdown of this year's flu season

January 6, 2026
theresa-g-avatar-small - light bg
Morning Rounds Writer and Reporter

Good morning. Over the holidays, I re-read "Wuthering Heights" in anticipation of the movie coming out next month — I still loved it, but I'm not sure I'll love the film. My question for you: Should I also re-read "The Odyssey" in advance of that movie? 

politics

Trump admin slashes childhood vax recs

Federal health officials are unilaterally reducing the number of recommended pediatric immunizations in response to an order from President Trump, marking the most significant reshaping of the vaccine schedule since Trump took office. The new schedule, announced yesterday, pares down the number of recommended vaccines from 17 to 11, recommends some shots only for "high-risk" individuals, and says that some others can be given through "shared clinical decision-making."

Officials claim the new schedule is meant to bring U.S. recommendations closer to those in other developed nations. Though as my colleagues have reported, some other wealthy countries actually have similar recommendations to the ones the administration is jettisoning. Get the details from STAT's Chelsea Cirruzzo and Helen Branswell. And keep an eye out for more reporting on this today.


new year, new flu

Why flu seems to be everywhere 

In other infectious disease news: You may have the impression that we're experiencing a particularly early or especially virulent flu season. You've probably read headlines on other sites referring to this wave of illness as a "super flu." (That's not a thing.) STAT's Helen Branswell has a story today answering all your questions on what's going on. 

"It's like with snow in New York City. It snows almost every year in New York City and people forget how to deal with it," flu expert Florian Krammer told Helen about the variance of each flu season. "And then it shows up again and they're like, 'Oh my God, what is that? How do we deal with that?'" Read more on what we know about this year's virus, the timing, and the vaccine. 


business

Private equity sees opportunity in autism

Between 2015 and 2025, private equity firms acquired more than 500 autism treatment centers in the U.S., with most (about 80%) of those acquisitions occurring between 2018 and 2022, according to a study published yesterday in JAMA Pediatrics. The increase in investment coincided with increasing diagnoses of the condition, especially among children, the study authors noted. 

The analysis showed that private equity was more likely to make acquisitions in states with higher prevalence of autism as well as more generous insurance coverage mandates. "The big takeaway is that there is yet another segment of health care that has emerged as potentially profitable to private equity investors and it is very distinct from where we have traditionally known investors to go," lead author Yashaswini Singh said in a press release. "So the potential for harm can be a lot more serious."

The study did not calculate the percentage of all therapy centers that were PE-owned, nor did it show how these acquisitions may have affected access to treatment. It's our first time saying it this year but it certainly won't be the last: More research is needed.



health tech

Are AI antibodies on the way?

3d bue medicine bottle with magnifying glass and antibodies inside.

Adobe 

Within the next couple years, a company will likely claim it has put the first artificial-intelligence-designed antibody in the clinic. But what, exactly, will that mean? Some researchers say that as long as a computer designs the basic antibody sequence, it counts as "AI-designed," even if scientists later tweak it to make a clinical candidate. But others say that an antibody should be ready to go straight into the clinic from the computer — a much bigger feat. 

The work is ongoing. Last year, scientist David Baker received part of the chemistry Nobel Prize for his research in computational protein design. Now, he's now turning his attention toward AI-designed antibodies. "The real question is, will this completely transform the industry? And how long will that take?" he told STAT's Brittany Trang. Read more on what antibody AI models achieved in 2025 and what work is ahead.


more guidelines

Goodbye, pap smears

Starting in 2027, women and others who are at an average risk for cervical cancer will have a new screening option covered by insurance. The Health Resources and Services Administration at HHS released updated HPV screening recommendations yesterday, adding a new option for people to self-collect samples from the vagina or have it done by a clinician. The hrHPV test specifically looks for high risk variants of the virus, which cause nearly all cervical cancer cases. 

Per the new guidelines, women ages 21 to 29 with average risk should still get pap smears every three years. But those ages 30 to 65 should do the hrHPV test every five years. (It's more like a PCR Covid test than a rapid one, for what it's worth: After collection, samples are sent to a lab where they're analyzed.) 

The change will likely be welcome news to people around the country who dread regular cervical exams by their doctors, or those who struggle to see a doctor. But as family physician Kenny Lin pointed out, this is typically a job for the U.S. Preventative Services Task Force, which health secretary Robert F. Kennedy Jr. has worked to overhaul.


first opinion

How to achieve the full potential of 'hospital at home' programs

The Center for Clinical Standards and Quality at CMS was "staring down a crisis" when Lee Fleisher took charge of the center in 2020. The Acute Hospital Care at Home waiver was born out of that crisis, allowing hospitals to deliver high-acuity care where most patients prefer: in their own homes.

Typically, the program's existence relies on a patchwork of short-term extensions — sometimes two years, sometimes just a few months. While the House recently passed a five-year extension, Senate action remains unclear ahead of a Jan. 30 deadline. Read more from the expert who oversaw the development of the program on its importance and its potential. 


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • Federal appeals court upholds ruling blocking NIH cap on research overhead payments, STAT
  • Iowa doesn't have enough OB-GYNs. The state's abortion ban might be making it worse, KFF Health News

  • With political savvy and outrage over drug prices, advocate David Mitchell was ahead of his time, STAT
  • At Middlebury, she hoped to start fresh. In Trump's America, it seemed impossible, New York Times

Thanks for reading! More next time,


Enjoying Morning Rounds? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.

No comments